CoChat

Antibiotics for the treatment of Cholera, Shigella and Cryptosporidiumin children

Open access
Das, Jai K, Ali, Anum, Salam, Rehana A, Bhutta, Zulfiqar A · 2013 · BMC Public Health
Cited by 53

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Diarrhea is a major contributor to the burden of morbidity and mortality in children; it accounts for a median of 11% of all deaths among children aged less than 5 years, amounting to approximately 0.8 million deaths per year. Currently there is a dearth of literature exploring the effectiveness of antibiotics for diarrhea due to Cholera, Shigella and cryptosporidiosis in children. METHODS: We reviewed the literature reporting the effect of antibiotics for the treatment of diarrhea due to Cholera, Shigella and Cryptosporidium in children under five years. We used a standardized abstraction and grading format and performed meta-analyses to determine the effect of the treatment with various antibiotics on mortality and rates of clinical and bacteriological/parasitological failure. The CHERG Standard Rules were applied to determine the final effect of treatment with antibiotics on diarrhea morbidity and mortality. RESULTS: For Cholera; the evidence was weak to recommend any effect on mortality. For Shigella; there was no data on mortality; either all-cause or cause specific, hence we used clinical failure rates as a proxy for Shigella deaths and propose that treatment of Shigella dysentery with antibiotics can result in a 82% reduction in diarrhea mortality due to Shigella. For cryptosporidiosis; there was data on all-cause mortality but the evidence was weak hence we used clinical failure rates as a proxy for mortality to estimate that antimicrobial treatment of diarrhea due to cryptosporidiosis can result in a 54% reduction in mortality. CONCLUSIONS: There is evidence to recommend antibiotic use for reduction of morbidity and mortality due to Cholera, Shigella and Cryptosporidium. We recommend that more clinical trials should be conducted to evaluate the efficacy and safety of first- and second- line drugs currently in use for treatment for diarrhea and dysentery in both developing and developed countries.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2458-13-s3-s10

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 33

  1. UNICEF: Levels & Trends in Child Mortality, Estimates Developed by the UN Inter-agency Group for Child Mortality Estimation. 2012, New York, NY: UNICEF
  2. Bhattacharya SK, Datta D, Bhattacharya MK, Garg S, Ramamurthy T, Manna B, Nair GB, Nag A, Moitra A: Cholera in young children in an endemic area. Lancet. 1992, 340 (8834-8835): 1549- · doi:10.1016/0140-6736(92)92804-o
  3. Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, Kim DR, Ali M, Clemens JD: The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis. 2008, 2 (2): e173-10.1371/journal.pntd.0000173. · DOI · Paper page
  4. Glass RI, Becker S, Huq MI, Stoll BJ, Khan MU, Merson MH, Lee JV, Black RE: Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol. 1982, 116 (6): 959-970. · DOI · Paper page
  5. Sack RB, Siddique AK, Longini IM, Nizam A, Yunus M, Islam MS, Morris JG, Ali A, Huq A, Nair GB, et al: A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh. J Infect Dis. 2003, 187 (1): 96-101. 10.1086/345865. · DOI · Paper page
  6. World Health Organization: Cholera, 2010. Weekly Epidemiological Record. 2010, 86 (31): 325-339.
  7. Siddique AK, Nasim SMA: Guidelines for Operating Makeshift Treatment Centres in Cholera Epidemics. 1997, ICDDR, B, Dhaka, Available at https://centre.icddrb.org/images/epidemics.pdf
  8. Nelson EJ, Nelson DS, Salam MA, Sack DA: Antibiotics for both moderate and severe cholera. N Engl J Med. 364 (1): 5-7. · doi:10.1056/nejmp1013771
  9. Amieva MR: Important bacterial gastrointestinal pathogens in children: a pathogenesis perspective. Pediatr Clin North Am. 2005, 52 (3): 749-777. 10.1016/j.pcl.2005.03.002. vi · DOI
  10. Ram PK, Crump JA, Gupta SK, Miller MA, Mintz ED: Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005. Epidemiol Infect. 2008, 136 (5): 577-603. · DOI
  11. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM: Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 1999, 77 (8): 651-666.
  12. Bardhan P, Faruque ASG, Naheed A, Sack DA: Decreasing Shigellosis-related Deaths without Shigella spp.-specific Interventions, Asia. Emerging Infectious Diseases. 2010, 16 (11): 1718-10.3201/eid1611.090934. · doi:10.3201/eid1611.090934
  13. Clark DP: New insights into human cryptosporidiosis. Clin Microbiol Rev. 1999, 12 (4): 554-563. · doi:10.1128/cmr.12.4.554
  14. Mosier DA, Oberst RD: Cryptosporidiosis. A global challenge. Ann N Y Acad Sci. 2000, 916: 102-111. · DOI
  15. Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM: Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet. 2002, 359 (9306): 564-571. 10.1016/S0140-6736(02)07744-9. · DOI · Paper page
  16. Ochoa TJ, Salazar-Lindo E, Cleary TG: Management of children with infection-associated persistent diarrhea. Semin Pediatr Infect Dis. 2004, 15 (4): 229-236. 10.1053/j.spid.2004.07.003. · DOI
  17. Smith HV, Corcoran GD: New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis. 2004, 17 (6): 557-564. 10.1097/00001432-200412000-00008. · doi:10.1097/00001432-200412000-00008
  18. Christopher PRH, David KV, John SM, Sankarapandian V: Antibiotic therapy for Shigella dysentery. The Cochrane Library. 2009
  19. Kabir I, Khan WA, Haider R, Mitra AK, Alam AN: Erythromycin and trimethoprim-sulphamethoxazole in the treatment of cholera in children. J Diarrhoeal Dis Res. 1996, 14 (4): 243-247.
  20. Roy SK, Islam A, Ali R, Islam KE, Khan RA, Ara SH, Saifuddin NM, Fuchs GJ: A randomized clinical trial to compare the efficacy of erythromycin, ampicillin and tetracycline for the treatment of cholera in children. Trans R Soc Trop Med Hyg. 1998, 92 (4): 460-462. 10.1016/S0035-9203(98)91094-X. · DOI
  21. Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group: Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J. 2002, 21 (12): 1136-1141. · DOI
  22. Alam AN, Islam MR, Hossain MS, Mahalanabis D, Hye HK: Comparison of pivmecillinam and nalidixic acid in the treatment of acute shigellosis in children. Scand J Gastroenterol. 1994, 29 (4): 313-317. 10.3109/00365529409094842. · DOI
  23. Salam MA, Dhar U, Khan WA, Bennish ML: Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet. 1998, 352 (9127): 522-527. 10.1016/S0140-6736(97)11457-X. · DOI
  24. Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I: Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr. 1991, 118 (4 Pt 1): 627-632. · DOI
  25. Haltalin KC, Nelson JD, Kusmiesz HT: Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch Dis Child. 1973, 48 (4): 305-312. 10.1136/adc.48.4.305. · DOI
  26. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P: Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 2002, 360 (9343): 1375-1380. 10.1016/S0140-6736(02)11401-2. · DOI · Paper page
  27. Rossignol JF, Ayoub A, Ayers MS: Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis. 2001, 184 (1): 103-106. 10.1086/321008. · DOI · Paper page
  28. Wittenberg DF, Miller NM, van den Ende J: Spiramycin is not effective in treating cryptosporidium diarrhea in infants: results of a double-blind randomized trial. J Infect Dis. 1989, 159 (1): 131-132. 10.1093/infdis/159.1.131. · DOI
  29. Sack DA, Sack RB, Nair GB, Siddique AK: Cholera. Lancet. 2004, 363 (9404): 223-233. 10.1016/S0140-6736(03)15328-7. · DOI · Paper page
  30. Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML: Single-dose azithromycin for the treatment of cholera in adults. New England Journal of Medicine. 2006, 354 (23): 2452-2462. 10.1056/NEJMoa054493. · DOI · Paper page
  31. Nelson EJ, Nelson DS, Salam MA, Sack DA: Antibiotics for both moderate and severe cholera. New England Journal of Medicine. 2011, 364 (1): 5-7. 10.1056/NEJMp1013771. · doi:10.1056/nejmp1013771
  32. Snelling WJ, Xiao L, Ortega-Pierres G, Lowery CJ, Moore JE, Rao JR, Smyth S, Millar BC, Rooney PJ, Matsuda M, et al: Cryptosporidiosis in developing countries. J Infect Dev Ctries. 2007, 1 (3): 242-256. · DOI
  33. Hunter PR, Nichols G: Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev. 2002, 15 (1): 145-154. 10.1128/CMR.15.1.145-154.2002. · DOI · Paper page

Cited by

See all 53

Metadata

Authors
Das, J. K., Ali, A., Salam, R. A., & Bhutta, Z. A.
Venue
BMC Public Health
Published
2013-09
Volume
13
Issue
S3
Pages
S10-S10
ISSN
1471-2458 (ISSN-L)
OpenAlex
W2080596239
Cited by
53
References
2
FWCI
5.40
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibiotics for the treatment of Cholera, Shigella and Cryptosporidiumin children. https://app.cochat.ai/papers/10.1186/1471-2458-13-s3-s10
The paper
Das, J. K., Ali, A., Salam, R. A., & Bhutta, Z. A. (2013). Antibiotics for the treatment of Cholera, Shigella and Cryptosporidiumin children. BMC Public Health. https://doi.org/10.1186/1471-2458-13-s3-s10

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.